Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Nkarta Therapeutics
6000 Shoreline Court, Suite 102
South San Francisco, CA 94080
https://www.nkartatx.com/

Nkarta Therapeutics was founded on the proprietary, robust and well characterized Natural Killer (NK) cell expansion technology pioneered by Dr. Dario Campana. The company is focused on leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. Nkarta is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of tumor targets, and improve persistence for sustained activity in the body for the treatment of cancer. Nkarta's goal is to develop off-the-shelf NK cell therapy product candidates to improve outcomes for patients.

Key Contact
Name
Paul Hastings
Title
CEO
E-Mail
Funding Events

Date
Amount
Type
Investors
Valuation
09/05/19 $114,000,000 Series B Amgen Business Development
Deerfield Management Company, L.P.
Life Sciences Partners
Logos Capital
NEA Ventures
Novo Holdings
RA Capital
Samsara BioCapital
SR One
undisclosed